English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/164733
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics

AuthorsMcKerrell, Thomas; Moreno, Thaidy; Varela, Ignacio CSIC ORCID; Vassiliou, George S.
Issue Date2017
PublisherAmerican Society of Hematology
CitationBlood Advances 1(14): 968-971 (2017)
AbstractThe JAK2 V617F mutation is the most common somatic mutation in the classical myeloproliferative neoplasms (MPNs), present in >95% of cases of polycythemia vera (PV) and ~50% of essential thrombocythemia (ET) and myelofibrosis (MF).1-4 It is usually the sole identifiable driver mutation in MPNs5 and was recently also identified as a driver of age-related clonal hemopoiesis in healthy individuals.6-9 In order to investigate the preclinical clonal evolution of MPNs, we identified 12 individuals with a JAK2 V617F mutant MPN, who 4.6 to 15.2 years previously (median 10.2 years) had also donated blood to register with the Cyprus Bone Marrow Donor Registry at the Karaiskakio Foundation
DescriptionMcKerrell, Thomas et al.
Publisher version (URL)https://doi.org/10.1182/bloodadvances.2017007047
Identifiersdoi: 10.1182/bloodadvances.2017007047
e-issn: 2473-9529
Appears in Collections:(IBBTEC) Artículos
Files in This Item:
File Description SizeFormat 
JAkinetics.pdf789,55 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.